scholarly journals Effectiveness and Safety of Acupuncture Moxibustion Therapy Used in Breast Cancer-Related Lymphedema: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-10 ◽  
Author(s):  
Huimin Jin ◽  
Yuying Xiang ◽  
Yuqian Feng ◽  
Yiting Zhang ◽  
Shan Liu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Moxibustion Therapy ◽  
Western Medicine ◽  
Methodological Quality ◽  
Meta Analysis ◽  
Karnofsky Performance Score ◽  
Performance Score ◽  
Functional Training ◽  
Breast Cancer Related Lymphedema

Objective. To evaluate the effectiveness and safety of acupuncture moxibustion therapy (AMT) for the breast cancer-related lymphedema (BCRL). Methods. Four English databases (MEDLINE, PubMed, Embase, and Cochrane CENTRAL) and four Chinese databases were searched from their inception to Feb 1, 2020. Eligible randomized controlled trials (RCTs) investigating AMT against any type of controlled intervention in patients for BCRL and assessing clinically relevant outcomes (total effective rate, circumference difference, and Karnofsky performance score) were included. The methodological quality of all selected trials was estimated in accordance with the guidelines published by the Cochrane Collaboration. Review Manager 5.3 was used to conduct analyses. Results. Twelve eligible RCTs are confirmed. Most of the trials selected are regarded as low methodological quality. Compared with Western medicine, physiotherapy, and functional training, traditional AMT has significantly higher treatment effect (RR 1.03 (95% CI: 1.22, 1.45); p<0.00001). In comparison with physiotherapy, AMT is better in reducing edema symptoms (MD = −0.77; 95% CI (−1.13–0.41); p<0.00001). Moreover, pooled results demonstrate that AMT results in better outcomes than functional training and Western medicine in improving Karnofsky performance score of BCRL patients (SMD = 0.69; 95% CI (0.38–1.00); p<0.00001). Conclusion. This systematic review and meta-analysis provides evidence that AMT is serviceable and safe in treating BCRL. With the limited number of available studies and methodology drawbacks, further high-quality RCTs with reasonable designs are still warranted.

scholarly journals Efficacy and Safety of Acupuncture-Moxibustion Therapy on Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-11
Author(s):  
Huimin Jin ◽  
Yuqian Feng ◽  
Yuying Xiang ◽  
Yiting Zhang ◽  
Wurong Du ◽  
...  
Keyword(s):  
Systematic Review ◽  
Moxibustion Therapy ◽  
Methodological Quality ◽  
Leukocyte Count ◽  
Meta Analysis ◽  
Karnofsky Performance Score ◽  
Efficacy And Safety ◽  
Performance Score ◽  
Statistical Results

Background. Acupuncture-moxibustion therapy (AMT), as an integral part of complementary and alternative medicine, has been used for centuries in treatment of numerous diseases. Nevertheless, there is no available supportive evidence on the efficacy and safety of acupuncture-moxibustion therapy in patients with chemotherapy-induced leukopenia (CIL). The purpose of this study is to evaluate the efficacy and safety of acupuncture-moxibustion therapy in treating chemotherapy-induced leukopenia. Methods. Relevant studies were searched in nine databases up to September 19, 2020. Two reviewers independently screened the studies for eligibility, extracted data, and assessed the methodological quality of selected studies. Meta-analysis of the pooled mean difference (MD) and risk ratio (RR) with their respective 95% confidence intervals (CI) were calculated. Results. 17 studies (1206 patients) were included, and the overall quality of the included studies was moderate. In comparison with medical therapy, AMT has a better clinical efficacy for CIL (RR, 1.24; 95% CI, 1.17-1.32; P < 0.00001 ) and presents advantages in increasing leukocyte count (MD, 1.10; 95% CI, 0.67–1.53; P < 0.00001 ). Also, the statistical results show that AMT performs better in improving the CIL patients’ Karnofsky performance score (MD, 5.92; 95% CI, 3.03–8.81; P < 0.00001 ). Conclusion. This systematic review and meta-analysis provides updated evidence that AMT is a safe and effective alternative for the patients who suffered from CIL.

scholarly journals Erratum to: Radiation therapy targets and the risk of breast cancer-related lymphedema: a systematic review and network meta-analysis

2017 ◽  
Vol 162 (2) ◽  
pp. 217-217
Author(s):  
Simona F. Shaitelman ◽  
Yi-Ju Chiang ◽  
Kate D. Griffin ◽  
Sarah M. De Snyder ◽  
Benjamin D. Smith ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Radiation Therapy ◽  
Meta Analysis ◽  
Therapy Targets ◽  
Breast Cancer Related Lymphedema

Acupuncture therapy for breast cancer‐related lymphedema: A systematic review and meta‐analysis

2019 ◽  
Vol 45 (12) ◽  
pp. 2307-2317 ◽  
Author(s):  
Wenzhen Hou ◽  
Lixia Pei ◽  
Yafang Song ◽  
Jian Wu ◽  
Hao Geng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Acupuncture Therapy ◽  
Meta Analysis ◽  
Breast Cancer Related Lymphedema

scholarly journals Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer

2019 ◽  
Vol 2019 ◽  
pp. 1-14 ◽  
Author(s):  
Dan Mao ◽  
Lei Feng ◽  
Siqi Huang ◽  
Shaofan Zhang ◽  
Weijun Peng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Confidence Interval ◽  
Cancer Patients ◽  
Tumor Response ◽  
Meta Analysis ◽  
Hepatic Function ◽  
Karnofsky Performance Score ◽  
Breast Cancer Patients ◽  
Performance Score ◽  
Review Manager

Objective. To systematically evaluate the efficacy of Xihuang pill (XHP) in breast cancer patients receiving chemotherapy. Methods. Three English and four Chinese databases were searched. Literature was screened using EndNote X7 and data were analyzed by Review Manager. Results. This review included 13 randomized clinical studies of 1272 patients. The results showed that XHP increased the tumor response [risk ratio (RR) = 2.91; 95% confidence interval (CI): 1.98-4.26] and improved Karnofsky performance score (KPS) for breast cancer patients receiving chemotherapy [RR = 4.96; 95% CI = 2.07-11.86]. In addition, XHP treatment significantly reduced chemotherapy-induced adverse events, including nausea and vomiting [RR = 0.50; 95% CI = 0.33-0.74], WBC reduction [RR = 0.71; 95% CI = 0.47-1.06], platelet reduction [RR = 0.53; 95% CI = 0.19-1.44], hemoglobin reduction [RR = 0.31; 95% CI = 0.19-0.52], and hepatic function damage [RR = 0.63; 95% CI = 0.35-1.11]. Conclusion. XHP combined with chemotherapy in comparison with chemotherapy alone could significantly enhance the tumor response, improve KPS, and alleviate toxicity induced by chemotherapy in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document